Retatrutide

Retatrutide is a novel synthetic peptide and the first triple receptor agonist to simultaneously target GIP, GLP-1, and glucagon receptors. it has demonstrated compelling results in clinical research for metabolic disease, making it one of the most closely watched compounds in obesity and cardiometabolic research today.

Mechanism By activating all three incretin and glucagon pathways simultaneously, Retatrutide drives synergistic effects on appetite suppression, energy expenditure, and glucose homeostasis.

Research Areas: Obesity & body weight reduction · Glucose regulation · Energy expenditure · Cardiometabolic health · Fatty liver disease (NAFLD/NASH)

For research use only. Not for human consumption.